Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) shares crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$0.43 and traded as high as C$0.45. Medicenna Therapeutics shares last traded at C$0.44, with a volume of 11,564 shares.
Medicenna Therapeutics Trading Up 10.0%
The firm has a market cap of C$40.61 million, a price-to-earnings ratio of -2.00 and a beta of 2.49. The business has a fifty day simple moving average of C$0.43 and a 200-day simple moving average of C$0.54. The company has a debt-to-equity ratio of 6.22, a quick ratio of 4.65 and a current ratio of 1.25.
Medicenna Therapeutics Company Profile
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
Featured Stories
- Five stocks we like better than Medicenna Therapeutics
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
